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Abstract
Introduction: Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant genetic syndrome caused by germline mutation 
in RET proto-oncogene. The most common mutations are in a cysteine rich domain. Phaeochromocytoma will develop in approximately 
50% of RET proto-oncogene carriers. 
Material and methods: The studied population consisted of 228 RET proto-oncogene mutation carriers. Monitoring for the diagnosis of 
phaeochromocytoma was carried out in all patients with established genetic status. Mean time of follow up was 138 months. Surveillance 
consisted of periodically performed clinical evaluation, 24-hour urinary determinations of total metanephrines complementary with 
imaging (CT, MR, MIBG scintigraphy). 
Results: Phaeochromocytoma developed in 41 patients (18% of all RET proto-oncogene mutations carriers). The mean age of diagnosis for 
the whole cohort was 43 years. In eight cases phaeochromocytoma was the first manifestation of the MEN 2 syndrome. Only eight (20%) 
patients were symptomatic at diagnosis of phaeochromocytoma. The mean size of the tumour was 4.3 cm. There was no extra-adrenal 
localisation. We observed one case of malignant phaeochromocytoma.
Conclusions: In patients with MEN 2 syndrome phaeochromocytomas are usually benign adrenal tumours with high risk of bilateral 
development. Taking to account the latter risk and non-specific clinical manifestation of the neoplasm it is mandatory to screen all RET 
proto-oncogene mutations carriers for phaeochromocytoma. (Endokrynol Pol 2016; 67 (1): 54–58)
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Streszczenie
Wstęp: Zespół mnogich nowotworów gruczołów dokrewnych typu 2 (MEN 2) jest schorzeniem uwarunkowanym genetycznie, dziedzi-
czonym w sposób autosomalny dominujący, spowodowanym mutacją germinalną protoonkogenu RET. W 80% przypadków mutacje 
zlokalizowane są w kodonie 634. Guz chromochłonny rozwinie się u 50% pacjentów z zidentyfikowaną mutacją w protoonkogenie RET.
Materiał i metody: 228 nosicieli mutacji w protonkogenie RET poddano monitorowaniu w kierunku rozwoju guza chromochłonnego. 
Nadzór obejmował okresowo wykonywane ocenę stanu klinicznego, wydalania metoksykatecholamin w dobowej zbiórce moczu kom-
plementarnie z diagnostyką obrazową (CT, MR, scyntygrafia MIBG).
Wyniki: Guz chromochłonny rozwinął się u 41 pacjentów (18% wszystkich pacjentów z ustaloną mutacją w protoonkogenie RET). Średni wiek 
rozpoznania wynosił 43 lata. W 8 przypadkach guz chromochłonny był pierwszą kliniczną manifestacją MEN 2. Tylko u 8 pacjentów (20%) 
w chwili rozpoznania obserwowano objawy kliniczne typowe dla guza chromochłonnego. Średnia wielkość guza wynosiła 4,3 cm. Nie 
stwierdzono poza nadnerczowej lokalizacji. W obserwacji autorów potwierdzono tylko jeden przypadek złośliwego guza chromochłonnego.
Wnioski: Guzy wywodzące się z tkanki chromochłonnej rozwijające się w przebiegu zespołu MEN 2 mają zwykle nadnerczową lokalizację 
i łagodny charakter jednak z dużą częstością zmian obustronnych. Biorąc pod uwagę powyższe ryzyko, a także niespecyficzny obraz 
kliniczny istotnym jest monitorowanie wszystkich pacjentów z potwierdzoną mutacją w protoonkogenie RET w kierunku rozwoju guza 
chromochłonnego. (Endokrynol Pol 2016; 67 (1): 54–58)
Słowa kluczowe: guz chromochłonny; MEN 2; analiza protoonkogenu RET
This research was supported by Polish National Science Centre grant no. NN401410639.
Introduction
Multiple endocrine neoplasia type 2 (MEN 2) is an 
autosomal dominant genetic syndrome, caused by ger-
mline mutation in RET proto-oncogene, which encodes 
a tyrosine kinase receptor. The RET proto-oncogene is 
located on chromosome 10 and consists of 21 exons. RET 
receptor forms together with the co-receptor, which is 
glial cell-derived neurotrophic factor family receptor-α-
1(GFRα1), the binary complex. The RET/GFRα1 complex 
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Results
The studied population consisted of 228 RET proto-
oncogene mutation carriers. The following distribution 
of RET mutations were observed in the cohort: 84 pa-
tients with codon 634 mutation (37%), 48 patients with 
codon 791 mutation (21%), 22 patients with codon 918 
mutation (10%), 19 patients with codon 618 mutation 
(8%), 15 patients with codon 620 mutation (6%), and the 
remaining 18% consisted of patients with mutations in 
codon 611, 768, 790, 804, 844, and 891.
Phaeochromocytoma developed in 41 patients (18% 
of all RET proto-oncogene mutation carriers), in 26 pa-
tients with codon 634 mutation (31%), in 6 patients with 
codon 918 mutation (27%), in 4 patients with codon 620 
mutation (27%), in 2 patients with codon 618 mutation 
(10.5%), in 2 patients with codon 791 mutation (4%), in 
1 patient with codon 611 mutation (25%).
The codon-specific penetrance of phaeochromocy-
toma is illustrated in Table I.
The mean age of diagnosis for the whole cohort was 
43 years. The age-related occurrence of phaeochromocyto-
ma is illustrated in Figure 1. The lowest age of diagnosis was 
observed in a 15-year-old patient with codon 918 mutation. 
The lowest age of diagnosis for the remaining codons were 
respectively: 20 years for codon 634, 29 years for codon 
620, 30 years for codon 791, 45 years for codon 618, and 
54 years for codon 611. In eight cases phaeochromocytoma 
was the first manifestation of MEN 2 syndrome, in 4 pa-
tients with codon 634 mutation, in 2 patients with codon 
791 mutation, in 1 patient with codon 918 mutation, and 
in 1 with codon 620 mutation. Codon-related occurrence 
of phaeochromocytoma and medullary thyroid cancer in 
MEN 2 syndrome is illustrated in Figure 2.
is activated by the ligand called glial cell-derived neuro-
trophic factor (GDNF) [1]. 
RET activation is required in the early embryos for 
the development of neural crest-derived cell types and 
the kidneys [2]. It also plays a role in growth stimulatory 
and anti-apoptotic functions. Single amino acid sub-
stitutions in the extracellular or intracellular domains 
of the receptor, which are the result of germline point 
mutations of RET, cause ligand-independent activation 
as a dimer or homodimer [3]. The most common muta-
tions are present in a cysteine-rich domain [1].
Different RET mutations are associated with dif-
ferent clinical phenotype. MEN 2 syndromes may be 
classified into three subtypes based on their occurrence. 
Medullary thyroid cancer (MTC) is characteristic for 
familiar medullary thyroid cancer (FMTC), MEN 2A 
and MEN 2B syndromes, while hyperparathyroidism 
occurs only in MEN 2A subtype, with penetrance of 
15–20% [1]. Phaeochromocytoma is observed in 50% of 
MEN 2A and MEN 2B cases [1]. In patients with MEN 2, 
phaeochromocytomas are usually benign, but the con-
sequences of abrupt secretion of catecholamines from 
the tumour may be lethal [4]. Taking in to account the 
latter risk and nonspecific clinical manifestation of the 
neoplasm and the fact that it develops usually after the 
diagnosis of medullary thyroid cancer, it is mandatory 
to screen all RET proto-oncogene mutations carriers for 
phaeochromocytoma.
Material and methods
We studied 228 patients with proto-oncogene RET 
mutations, registered in the Department of Nuclear 
Medicine and Endocrine Oncology, Maria Skłodowska-
Curie Memorial Cancer Centre and Institute of Oncol-
ogy, Gliwice Branch. 
Genetic analysis of RET proto-oncogene was per-
formed in each patient with confirmed medullary thy-
roid cancer, phaeochromocytoma, and positive family 
history of MEN 2.
The monitoring for the diagnosis of phaeochromo-
cytoma was carried out in all patients with established 
genetic status. Mean time of follow up was 138 months. 
Surveillance consisted of periodically performed clini-
cal evaluation, 24-hour urinary determinations of total 
metanephrines complementary with imaging (CT, MR, 
MIBG scintigraphy). To locate phaeochromocytoma, CT 
and MR were used without distinguishing between the 
effectiveness of these modalities. The size of the tumour 
was assessed using imaging modalities. The diagnosis 
of phaeochromocytoma each time was confirmed by 
histopathological analysis after adrenalectomy. All 
patients after surgery were under surveillance toward 
the recurrence or contralateral phaeochromocytoma.
Table I. Codon-specific expression of phaeochromocytoma 
in MEN 2
Tabela I. Penetracja guza chromochłonnego w zespole MEN 2 
w zależności od lokalizacji mutacji
Codon Positive incidence Total
611 1 (25.0%) 4
618 2 (10.5%) 19
620 4 (27.0%) 15
634 26 (31.0%) 84
768 0 (0.0%) 1
790 0 (0.0%) 9
791 2 (4.0%) 48
804 0 (0.0%) 17
844 0 (0.0%) 8
891 0 (0.0%) 1
918 6 (27.0%) 22
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patient with mutation in codon 791. The 10-cm tumour 
was revealed at the age of 30 years, and the metastases 
occurred after nine years of observation.
Of the 41 patients with phaeochromocytoma, 
11 (25%) had bilateral involvement at the time of di-
agnosis, and 14 (34%) revealed contralateral tumour 
throughout the follow-up period. From the whole 
group of patients with bilateral tumours, most (84%) 
had total bilateral adrenalectomy, which resulted in 
the development of adrenal insufficiency. Only four 
patients (16%) had adrenal-sparing surgery, of which 
only one did not require substitution of hydrocortisone. 
The clinical traits of phaeochromocytoma in MEN 
2 syndrome are shown in Table II.
Discussion
In our series phaeochromocytoma developed in pa-
tients with mutations at codons 611, 618, 620, 634, and 
918 of RET gene. Other studies observed phaeochromo-
cytoma in subjects with mutations at codon: 609, 618, 
620, 634, 666, 791, 804, 883, and 918 of RET gene [7–11].
The expected frequency of phaeochromocytoma in 
MEN 2 syndrome is up to 50% [6]. But its penetrance is 
highly dependent on the RET codon mutations [7, 8].
In our study in the whole cohort of RET proto-on-
cogene mutation carriers the overall rate of phaeochro-
mocytoma was 18%, which is similar to that reported 
by Nguyen et al. [9]. However, we observed higher 
frequency of the neoplasm (respectively, 31% and 27%) 
in patients with mutations at codon 634 and 918, which 
is very close to that reported by Machens et al. [8].
In the study by Rodriguez et al. they registered 
a 32% frequency of phaeochromocytoma in a cohort 
of 54 patients, among which 52 had mutation located 
in codon 634 [10].
Quayle at al. reported an overall rate of phaeo-
chromocytoma of 32%, with the greatest expression 
in codon 634 (50% positive incidence of phaeochro-
mocytoma) [7].
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Figure 1. Age-related occurrence of phaeochromocytoma in MEN 2
Rycina 1. Penetracja guza chromochłonnego w zespole MEN 2 
w zależności od wieku
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Figure 2. Codon-related mean occurrence age of medullary thyroid 
cancer and phaeochromocytoma in MEN 2
Rycina 2. Średni wiek ujawnienia raka rdzeniastego tarczycy 
I guza chromochłonnego w zespole MEN 2 w zależności od 
lokalizacji mutacji w poszczególnych kodonach
Table II. Clinical characteristics of phaeochromocytoma (PC) in MEN 2
Tabela II. Kliniczna charakterystyka guza chromochłonnego w zespole MEN 2
RET codon Total patient 
no.
Mean age 
at diagnosis 
(range) (year)
PC as the  
first tumour
Typical  
clinical 
symptoms
Mean size of 
the tumour 
[cm]
Bilateral 
tumour
Contralateral 
tumour during 
follow up
Metastases
611 1 54 (54–54) 0 0 3.1 1 0 0
618 2 51 (45–58) 0 0 2.3 2 0 0
620 3 44 (29–61) 1 1 3.6 1 1 0
634 24 36 (20–54) 4 2 2.7 6 9 0
791 2 49 (30–68) 2 2 8.0 0 0 1
918 6 23 (15–32) 1 1 6.2 1 4 0
Only 8 (20%) patients were symptomatic at diag-
nosis of phaeochromocytoma. The mean size of the 
tumour was 4.3 cm. There was no extra-adrenal localisa-
tion. We observed one case of malignant phaeochromo-
cytoma with metastases to lymph nodes in the female 
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The low penetrance of phaeochromocytoma in our 
group of patients may be due to the fact that we still 
have under surveillance 66 patients (29%) below the 
age of thirty years. Taking in to account that the peak 
age for revealing the phaeochromocytoma in MEN 2 
syndrome is estimated around 40 years [1], we expect 
that more cases of phaeochromocytoma will occur in 
our population.
The earliest manifestation of phaeochromocytoma 
in our study was in a 15-year-old patient with mutation 
in codon 918, while mean age of diagnosis was assessed 
as 43 years for the whole cohort of RET proto-oncogene 
mutations carriers. The youngest age at diagnosis 
of phaeochromocytoma reported in literature was 
12 years, also in a codon 918 mutation carrier [9]. But 
others observed early manifestation at the age of 
12 years in the case of a patient with mutation in codon 
634 [12]. The youngest patient age ever reported with 
disclosed phaeochromocytoma determines the moment 
of implementation of screening protocol. According 
to the guidelines for diagnosis and therapy of MEN 2 
published in 2001 the screening for phaeochromocy-
toma should be implemented by the age of 5–7 years 
in high- and highest-risk codon (630, 634, 883, 918 RET 
mutation carriers). In families with mutation in lower-
risk codons screening may be initiated at a later age. 
The familial pattern of phaeochromocytoma should be 
considered during the development of a screening plan 
[13]. The American Thyroid Association also stratifies 
the risk of phaeochromocytoma by RET genotype and 
recommends commencement of phaeochromocytoma 
screening by age of 8 years for mutated RET codons 630, 
634, and 918 and by age 20 years for the remainder [14].
The oldest patient in whom phaeochromocytoma 
was detected was 61 years old, a RET proto-oncogene 
mutation carrier in codon 620. In other studies the oldest 
age was 73 years [7]. However, it must be emphasised 
that age at detection does not necessarily reflect the 
age of onset. 
Thanks to the growth of availability of genetic 
screening, most patients under a follow-up regimen 
because of detected mutation in RET proto-oncogene 
are asymptomatic at the time of phaeochromocytoma 
diagnosis. 
In this study only 20% of patients presented typical 
symptoms. In the literature it is also emphasised that 
patients with MEN 2-related phaeochromocytoma often 
lack sustained hypertension or other symptoms [1]. But 
the incidence of asymptomatic patients reported in 
other studies is lower than that observed in our cohort, 
and ranges between 36 and 52% [7–10, 15]. Nguyen 
et al. reported that none of the patients in his series 
expressed all of the classical symptoms (hypertension, 
postural hypotension, palpitations, headaches, exces-
sive sweating) [9]. We took into consideration that the 
clinical evaluation in our study might be imperfect due 
to the retrospective character of analysis with a lack of 
some information in available medical records, and 
due to known difficulties in assessing symptoms of 
phaeochromocytoma sometimes mimicking other enti-
ties. Likewise, the extensive genetic screening in family 
members of RET mutations carriers may impact the low 
incidence of symptomatic cases acquired in this report. 
In eight patients (20%) phaeochromocytoma was the 
first manifestation of multiple endocrine neoplasia type 
2, which is comparable with data that phaeochromocy-
toma may be diagnosed before medullary thyroid can-
cer in 9–27% [16–18]. However, Nguyen et al. reported 
no phaeochromocytoma preceding MTC [9].
In our study all tumours were localised in adrenals. 
These results are in agreement with literature data. 
In a multicentre analysis of 563 MEN 2 patients with 
phaeochromocytoma extra-adrenal tumours occurred 
only in five patients [19]. Localisation of the tumour 
together with biochemical phenotype may be helpful 
in ordering proper genetic testing [20]. In our analysis 
results of 24-hour urinary fractioned metanephrines, 
unlike the total metanephrines, were available only in 
some cases due to limited availability of this modality 
in patients who were diagnosed a few years ago and 
outside the clinical centres. According to the algorithm 
proposed by the Endocrine Society, adrenal localisa-
tions of phaeochromocytoma together with significant 
productions of metanephrine relative to combined 
production of all three catecholamine metabolites, in 
the absence of a syndromic or familial presentation, 
guide selection of RET proto-oncogene as a first step 
in genetic analysis [20].
Bilateral phaeochromocytomas at the time of diag-
nosis were observed in 25% of patients in this cohort, 
and 34% revealed contralateral tumour throughout the 
follow-up period. The reported frequency of bilateral-
ism is variable in published reports, ranging between 
35% and 80% [7, 8, 21, 22] and is higher in comparison 
to sporadic cases, which is estimated at 3% [13]. Accord-
ing to that fact, patients with MEN 2 are at high risk for 
bilateral adrenalectomy and lifelong steroid depend-
ence. In our data only four patients had adrenal-sparing 
surgery that enables assessment of the outcomes of 
such a procedure. Castinetti et al. in a multicentre study 
showed that adrenal insufficiency is greatly reduced 
in adrenal-sparing operations compared with total 
adrenalectomies [19]. It is known that one third to one 
half of an adrenal gland is needed to preserve cortical 
function [20]. On the other hand, leaving some adrenal 
medullary tissue during non-radical surgery may be the 
cause of phaeochromocytoma recurrence. The cumula-
tive recurrence rate for MEN 2 patients after adrenal-
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sparing surgery at 10 years is 38.5% [20]. Nonetheless, 
Castinetti et al. have shown no significant difference in 
recurrences between those operated on with adrenal-
sparing surgery or with adrenalectomy. In material from 
the Department of General, Vascular, and Transplant 
Surgery, Medical University of Warsaw, Poland, in the 
case of phaeochromocytoma as a part of MEN 2, the 
lesions in adrenals have always been multiple [23]. The 
authors of the analysis emphasise the importance of 
precise assessment of the lesions with use of 3D CT in 
patients qualified for a sparing surgery [23].
In our study there was only one case (2%) of malig-
nant phaeochromocytoma, which corresponds with the 
opinion that MEN 2-associated phaeochromocytomas 
are almost exclusively benign [1, 19].
Conclusions
It is mandatory to screen all RET proto-oncogene muta-
tions carriers for phaeochromocytoma.
In patients with MEN 2 syndrome phaeochromo-
cytomas are usually benign adrenal tumours with high 
risk of bilateral development. Patients who present 
unilateral phaeochromocytoma should be monitored 
for early diagnosis of contralateral tumour.
Taking into account that medullary thyroid carci-
noma is the first manifestation of MEN 2 syndrome 
in most cases, it is recommended mandatory genetic 
study of RET proto-oncogene after diagnosis of MTC. 
Patients with confirmed germline RET mutation need 
careful screening for phaeochromocytoma before thy-
roid resection.
References
1. Pacak K, Timmers H, Eisenhofer G. Pheochromocytoma. In: Jameson 
JL, De Groot LJ. Endocrinology. Saunders Elsevier, Philadelphia 2010; 
1990–2018.
2. Schuchardt A, D’Agati V, Larsson-Blomberg L et al. Defects in the kidney 
and enteric nervous system of mice lacking the tyrosine kinase receptor 
Ret. Nature 1994; 367: 380–383.
3. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in 
development and cancer. Cytokine Growth Factor Rev 2005; 16: 
441–467.
4. Eng C, Clayton D, Schuffenecker I et al. The relationship between RET 
proto-oncogene mutations and disease phenotype in multiple endocrine 
neoplasia type 2. International RET Mutations Consortium analysis. 
JAMA 1996; 276: 1575–1579.
5. Lenders JW, Eisenhofer G, Manneli M et al. Pheochromocytoma. Lancet 
2005; 366: 665–675.
6. Wells SA, Pacini F, Robinson BG et al. Multiple endocrine neoplasia type 
2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol 
Metab 2013; 98: 3149–3146. doi:10.1210/jc.2013-1204
7. Quayle FJ, Fialkowski EA, Benveniste R et al. Pheochromocytoma 
penetrances varies by RET mutation in MEN 2A. Surgery 2007; 142: 
800–805.
8. Machens A, Brauckhoff M, Holzhausen HJ et al. Codon-specific devel-
opment of pheochromocytoma in multiple endocrine neoplasia type 2. 
J Clin Endocrinol Metab 2005; 90: 3999–4003.
9. Nguyen L, Niccoli-Sire P, Caron P et al. Pheochromocytoma in multiple 
endocrine neoplasia type 2: a prospective study. Eur J Endocrinol 2001; 
144: 37–44.
10. Rodriguez JM, Balsalobre M, Ponce JL et al. Pheochromocytoma in MEN 
2A syndrome. Study of 54 patients. World J Surg 2008; 32: 2520–2526. 
doi: 10.1007/s00268-008-9734-2
11. Thosani S, Ayala-Ramirez M, Palmer L et al. The characterization of 
pheochromocytoma and its impact on overall survival in multiple en-
docrine neoplasia type 2. J Clin Endocrinol Metab 2013; 98: 1813–1819. 
doi: 10.1210/jc.2013-1653
12. Machens A, Niccoli-Sire P, Hoegel J et al. Early malignant progres-
sion of hereditary medullary thyroid cancer. N Engl J Med 2003; 349: 
1517–1525.
13. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and 
therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 
86: 5658–5671.
14. Kloos RT, Eng C, Evans DB et al. Medullary Thyroid Cancer: manage-
ment guidelines of the American Thyroid Association. Thyroid 2009; 19: 
565–612. doi: 10.1089/thy.2008.0403
15. Myśliwiec J, Siewko K, Zukowski L et al. Pheochromocytoma — analysis 
of 15 consecutive cases from one center. Endokrynol Pol 2013; 64:192–196.
16. Casanova S, Rosenberg-Bourgin M, Farkas D et al. Pheochromocytoma 
in multiple endocrine neoplasia type 2A: survey of 100 cases . Clin 
Endocrinol 1993; 38: 531–537.
17. Inabnet WB, Caragliano P, Pertsemlidis D. Pheochromocytoma: inher-
ited associations, bilaterality and cortex preservation. Surgery 2000; 
128: 1007–1011.
18. Neumann HP, Berger DP, Sigmund G et al. Pheochromocytomas, multi-
ple endocrine neoplasia type 2 and von Hippel-Lindau disease. N Engl 
J Med 1993; 329: 1531–1538 
19. Castinetti F, Qi XP, Walz MK et al. Outcomes of adrenal-sparing sur-
gery or total adrenalectomy in pheochromocytoma associated with 
multiple endocrine neoplasia type 2: an international retrospective 
population-based study. Lancet Oncol 2014; 15: 648–655. doi: 10.1016/ 
/S1470-2045(14)70154-8
20. Lenders JW, Duh QY, Eisenhofer G et al. Pheochromocytoma and 
paraganglioma: An Endocrine Society clinical practice guideline. J Clin 
Endocrinol Matab 2014; 99: 1915–1942. doi: 10.1210/jc.2014-1498
21. Modigliani E, Vasen HM, Rue K et al. Pheochromocytoma in multiple 
endocrine neoplasia type 2A: European study. The Euromen Study 
Group. I Intern Med 1995; 238: 363-367.
22. Howe JR, Norton JA, Wells SA. Prevalence of pheochromocytoma and 
hyperparathyroidism in multiple neoplasia type 2A: results of long term 
follow up. Surgery 1993; 114: 1070–1077.
23. Otto M, Dzwonkowski J. Adrenal-preserving surgery of adrenal tumors. 
Endokrynol Pol 2015; 66: 80–96. doi: 10.5603/EP.2015.0012
